Entering text into the input field will update the search result below

Eli Lilly Q3 top line up 5%; net income down 3%; shares off 1% premarket

Oct. 25, 2016 7:38 AM ETEli Lilly and Company (LLY) StockBy: Douglas W. House, SA News Editor2 Comments
  • Eli Lilly (NYSE:LLY) Q3 results ($M): Total Revenues: 5,191.7 (+4.7%); Animal Health: 706.2 (-9.3%).
  • Net Income: 778.0 (-2.7%); Non-GAAP Net Income: 931.0 (-2.0%); EPS: 0.73 (-2.7%); Non-GAAP EPS: 0.88 (-1.1%).
  • Key Product Sales: Humalog: 640.8 (-9.1%); Cialis: 588.2 (+3.9%); Alimta: 570.4 (-9.2%); Forteo: 391.2 (+12.1%); Humulin: 322.0 (+1.7%); Cymbalta: 313.5 (+29.1%); Trulicity: 243.6 (+230.5%); Strattera: 198.8 (+1.0%); Erbitux: 184.6 (+114.9%); Cyramza: 159.0 (+43.0%); Zyprexa: 148.9 (-37.4%); Effient: 127.7 (-3.3%).
  • 2016 Guidance: Revenue: $20.8B - 21.2B (unch); EPS: $2.66 - 2.76 from $2.68 - 2.78; Non-GAAP EPS: $3.50 - 3.60 (unch).

Recommended For You

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company